Patents by Inventor Yasuo Sugiyama

Yasuo Sugiyama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7498352
    Abstract: The present invention provides a TGF-? superfamily production/secretion promoter comprising a compound represented by the formula wherein R1 is a halogen atom, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally substituted thiol group or an optionally substituted amino group; A is an optionally substituted acyl group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group or an optionally esterified or amidated carboxyl group; B is an optionally substituted aromatic group; X is an oxygen atom, a sulfur atom or an optionally substituted nitrogen atom; and Y is a divalent hydrocarbon group or heterocyclic group, or a salt thereof or a prodrug thereof, which is useful as an agent for the prophylaxis or treatment of dysautonomia, bladder dysfunction, hearing impairment, bone disease and the like.
    Type: Grant
    Filed: June 25, 2002
    Date of Patent: March 3, 2009
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yasuo Sugiyama, Masatoshi Hazama, Asae Shintani
  • Patent number: 7462635
    Abstract: The present invention provides a VDAC regulator comprising a compound represented by the formula (I): wherein R1 is a halogen atom, an optionally substituted heterocyclic group, an optionally substituted hydroxyl group, an optionally substituted thiol group or an optionally substituted amino group; A is an optionally substituted acyl group, an optionally substituted heterocyclic group, an optionally substituted hydroxyl group or an optionally esterified or amidated carboxyl group; B is an optionally substituted aromatic group; X is an oxygen atom, a sulfur atom or an optionally substituted nitrogen atom; and Y is a divalent hydrocarbon group or heterocyclic group; a salt thereof or a prodrug thereof, which is useful as an agent for the prophylaxis or treatment of Down's syndrome and the like.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: December 9, 2008
    Assignees: Takeda Pharmaceutical Company Limited, Tokyo Institute of Technology
    Inventors: Yasuo Sugiyama, Masatoshi Hazama, Norihisa Iwakami
  • Publication number: 20080153801
    Abstract: This invention provides new benzoxazepine compounds represented by the formula: [wherein R stands for a lower alkyl group optionally substituted with a hydroxyl group, X stands for an optionally substituted carbamoyl group or an optionally substituted heterocyclic group having a deprotonatable hydrogen atom, R1 stands for a lower alkyl group and W stands for a halogen atom] having activities of lowering chlesterol-level and lowering trigluceride-level, and being useful for prophylaxis and therapy of hyperlipidemia.
    Type: Application
    Filed: November 19, 2007
    Publication date: June 26, 2008
    Inventors: Hidefumi Yukimasa, Yasuo Sugiyama, Ryuichi Tozawa
  • Publication number: 20080132483
    Abstract: The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; as well as a ubiquinone increasing agent comprising a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof.
    Type: Application
    Filed: January 17, 2008
    Publication date: June 5, 2008
    Inventors: Yasuo Sugiyama, Tomoyuki Nishimoto, Yoshihiro Kiyota
  • Publication number: 20070117787
    Abstract: This invention provides new benzoxazepine compounds represented by the formula: [wherein R stands for a lower alkyl group optionally substituted with a hydroxyl group, X stands for an optionally substituted carbamoyl group or an optionally substituted heterocyclic group having a deprotonatable hydrogen atom, R1 stands for a lower alkyl group and W stands for a halogen atom] having activities of lowering cholesterol-level and lowering triglyceride-level, and being useful for prophylaxis and therapy of hyperlipidemia.
    Type: Application
    Filed: December 12, 2006
    Publication date: May 24, 2007
    Inventors: Hidefumi Yukimasa, Yasuo Sugiyama, Ryuichi Tozawa
  • Publication number: 20060241096
    Abstract: The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; as well as a ubiquinone increasing agent comprising a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof.
    Type: Application
    Filed: June 23, 2006
    Publication date: October 26, 2006
    Inventors: Yasuo Sugiyama, Tomoyuki Nishimoto, Yoshihiro Kiyota
  • Publication number: 20060242716
    Abstract: The present invention provides a non-human mammal, or a part of its living body, which stably retains a DNA encoding a heterologous PPAR? in an expressible state, and has one or more different genetic modifications resulting in a pathological condition identical or similar to a disease associated with the regulation of PPAR? activity or a foreign DNA under the control of a promoter having PPRE, as well as a method of screening for agonists/antagonists for the heterologous PPAR? using the animal.
    Type: Application
    Filed: July 14, 2003
    Publication date: October 26, 2006
    Inventors: Yuichiro Amano, Yasuo Sugiyama, Mayumi Nishida, Shigehisa Taketomi
  • Publication number: 20050239854
    Abstract: An agent for inhibiting body weight gain derived from a PPAR? agonist-like substance, which contains a PPAR? agonist-like substance, is useful for the treatment of diabetes and the like.
    Type: Application
    Filed: June 29, 2005
    Publication date: October 27, 2005
    Inventors: Yasuo Sugiyama, Hiroyuki Odaka, Hiroyuki Kimura
  • Publication number: 20050234116
    Abstract: The present invention provides a VDAC regulator comprising a compound represented by the formula (I): wherein R1 is a halogen atom, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally substituted thiol group or an optionally substituted amino group; A is an optionally substituted acyl group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group or an optionally esterified or amidated carboxyl group; B is an optionally substituted aromatic group; X is an oxygen atom, a sulfur atom or an optionally substituted nitrogen atom; and Y is a divalent hydrocarbon group or heterocyclic group, a salt thereof or a prodrug thereof, which is useful as an agent for the prophylaxis or treatment of Down's syndrome and the like, and the like.
    Type: Application
    Filed: March 13, 2003
    Publication date: October 20, 2005
    Inventors: Yasuo Sugiyama, Masatoshi Hazama, Norihisa Iwakami
  • Publication number: 20040204500
    Abstract: The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; as well as a ubiquinone increasing agent comprising a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof.
    Type: Application
    Filed: December 11, 2003
    Publication date: October 14, 2004
    Inventors: Yasuo Sugiyama, Tomoyuki Nishimoto, Yoshihiro Kiyota
  • Publication number: 20040142988
    Abstract: The present invention provides a TGF-&bgr; superfamily production/secretion promoter comprising a compound represented by the formula 1
    Type: Application
    Filed: December 16, 2003
    Publication date: July 22, 2004
    Inventors: Yasuo Sugiyama, Masatoshi Hazama, Asae Shintani
  • Publication number: 20040077689
    Abstract: The ABCA1 mRNA expression-promoting agent, LXR&agr; mRNA expression-promoting agent, ABCG1 mRNA expression-promoting agent, cholesterol efflux-promoting agent, cholesteryl ester accumulation-inhibiting agent, ACAT-1 mRNA expression-inhibiting agent and CEH mRNA expression-promoting agent of the present invention are excellent in the ability to control cholesterol distribution in the body and have low toxicity.
    Type: Application
    Filed: October 16, 2003
    Publication date: April 22, 2004
    Inventors: Yasuo Sugiyama, Hiromatsu Fuse, Masao Hirakata, Ryuichi Tozawa
  • Publication number: 20040072819
    Abstract: This invention provides new benzoxazepine compounds represented by the formula: 1
    Type: Application
    Filed: June 24, 2003
    Publication date: April 15, 2004
    Applicant: Takeda Chemical Industries, Ltd.
    Inventors: Hidefumi Yukimasa, Yasuo Sugiyama, Ryuichi Tozawa
  • Patent number: 6613761
    Abstract: This invention provides new benzoxazepine compounds represented by the formula: [wherein R stands for a lower alkyl group optionally substituted with a hydroxyl group, X stands for an optionally substituted carbamoyl group or an optionally substituted heterocyclic group having a deprotonatable hydrogen atom, R1 stands for a lower alkyl group and W stands for a halogen atom] having activities of lowering cholesterol-level and lowering trigluceride-level, and being useful for prophylaxis and therapy of hyperlipidemia.
    Type: Grant
    Filed: June 6, 2000
    Date of Patent: September 2, 2003
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Hidefumi Yukimasa, Yasuo Sugiyama, Ryuichi Tozawa
  • Publication number: 20030134884
    Abstract: An angiogenesis inhibitor containing a compound represented by the formula 1
    Type: Application
    Filed: September 26, 2002
    Publication date: July 17, 2003
    Inventors: Masatoshi Hazama, Takeshi Miyazaki, Yasuo Sugiyama
  • Patent number: 6545009
    Abstract: 1,3-Azole derivatives, pharmaceutical compositions thereof and methods for regulating the function of retinoid-related receptors with 1,3-azole derivatives are disclosed. Such regulation may be useful for preventing or treating diabetes, preventing or treating hyperlipidemia, preventing or treating impaired glucose tolerance (IGT) or for preventing transition from impaired glucose tolerance to diabetes.
    Type: Grant
    Filed: December 28, 2000
    Date of Patent: April 8, 2003
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Yasuo Sugiyama, Yu Momose, Hiroyuki Kimura, Junichi Sakamoto, Hiroyuki Odaka
  • Publication number: 20030060488
    Abstract: A TNF-&agr; inhibitor comprising an insulin sensitizer in combination with an HMG-CoA reductase inhibitor is useful as an agent for the prophylaxis or treatment of an inflammatory disease and the like.
    Type: Application
    Filed: August 9, 2002
    Publication date: March 27, 2003
    Inventors: Yasuo Sugiyama, Hiroyuki Odaka, Ken-ichi Naruo
  • Publication number: 20030040490
    Abstract: A pharmaceutical agent comprising only an &agr;-glucosidase inhibitor in combination with a non-sulfonylurea insulinsecretagogue as active ingredients is useful as an agent for the prophylaxis or treatment of diabetes and the like.
    Type: Application
    Filed: August 21, 2002
    Publication date: February 27, 2003
    Inventors: Yasuo Sugiyama, Hiroyuki Odaka, Hiroshi Sakiyama, Masato Iwasaki, Masami Funatsu
  • Publication number: 20030018040
    Abstract: There is provided a TNF-&agr; inhibitor comprising at least one compound selected from cerivastatin, atorvastatin, simvastatin, pravastatin, itavastatin and (+)-(3R, 5S)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino) pyrimidin-5-yl]-3,5-dihydroxy-6 (E)-heptenoic acid, or a salt thereof, which is excellent in the preventing and treating effects to TNF-&agr; -associated diseases such as inflammatory disease and has the sufficiently excellent nature as a medicine, such as absence of side effect.
    Type: Application
    Filed: August 8, 2002
    Publication date: January 23, 2003
    Inventors: Yasuo Sugiyama, Hiroyuki Odaka, Ken-ichi Naruo, Masami Funatsu, Kazuaki Ikeya, Yoshiharu Suzuki
  • Patent number: 6235731
    Abstract: A novel compound of the formula: wherein ring Q is an optionally substituted pyridine ring; One of R0, R1 and R2 is —Y0—Z0, and the other tow groups are a hydrogen, a halogen, an optionally substituted hydroxy group, a hydrocarbon group that may be an optionally substituted hydrocarbon group or an acyl group; Y0 is a bond or an optionally substituted bivalent hydrocarbon group; Z0 is a basic group which may be bonded via oxygen, nitrogen, —CO—, —CS—, —SO2N(R3)— (where R3 is hydrogen or an optionally substituted hydrocarbon group), or S(O)n (wherein n is to 0, 1 or 2); ......... is a single bond or a double bond, or a salt thereof, which has an excellent LDL receptor up-regulating, blood-lipids lowering, blood-sugar lowering and diabetic complication-ameliorating activity.
    Type: Grant
    Filed: October 8, 1998
    Date of Patent: May 22, 2001
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Yumiko Shibouta, Yasuo Sugiyama, Tetsuji Kawamoto, Muneo Takatani